Endocyte, Inc. Still Has Huge Potential Post-90% Pop

The biggest winner on the market Friday was Endocyte (NASDAQ: ECYT  ) by a long shot, as shares absolutely exploded, closing upwards of 90% for the day. The market was celebrating a successful phase 2 clinical trial of the company's drug vintafolide in its lung cancer indication. When combined with chemotherapy, the drug gave patients a 25% benefit both in progression-free survival rates and overall survival rates. In addition, the company received EU approval for vintafolide in the treatment of ovarian cancer.

These two catalysts have caused analyst price targets to jump, with Piper Jaffray coming out and raising its target on the stock to $36; shares currently sit at $28. In this segment from Friday's Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass discuss Endocyte's partnership with Merck (NYSE: MRK  ) on the drug, as well as just how much blockbuster potential the drug could have, and why even after a near double the stock is filled with upside.

Looking for more explosive growth stocks?
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Read/Post Comments (2) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 23, 2014, at 4:16 AM, marp11 wrote:

    thats nice but when ARNA has the BELVIQ ads hot TV in 2-4 weeks, watch the 57 million shorts send it to 50

  • Report this Comment On May 12, 2014, at 5:31 PM, anathestalker wrote:

    OoH~ bad call on Indocyte. I wonder how many ppl ate dirt b/c of this.

    Goes to show do not trust anyone unless you practically understand the business yourself.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2886215, ~/Articles/ArticleHandler.aspx, 12/20/2014 5:01:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement